Ernexa Therapeutics Inc. (ERNA)
ERNA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/748592/000149315226010102/0001493152-26-010102-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ERNA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000748592 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $582K |
| Net income | -$44.5M |
| Operating income | -$15.7M |
| Net margin | -7652.7% |
| Operating margin | -2693.1% |
| Revenue growth | +755.9% |
| Cash | $1.7M |
| Total assets | $5.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 4.9× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "In connection with preparing the financial statements as of and for the three and nine months ended September 30, 2026, the Company evaluated whether there are conditions and events, considered in the aggregate, that are known and reasonably knowable that would raise substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued." | 10-Q 2026-11-06 |
| Cash and burn | $5.6M cash; operating cash flow -$2.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,692,550 (2026-11-06); 7,848,889 a year earlier; 5,410,331 three years earlier. 1y figure adjusted for splits (1-for-25 overall); 3y figure adjusted for splits (1-for-375 overall). | Cover page 2026-11-06 |
| Reverse splits, 3 years | 2; latest 1-for-25 on 2026-05-04 | Source 2026-05-04 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns | Latest 2026-02-10 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-03-20 |
| Auditor | Haskell & White LLP, Irvine, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-07-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$2.9M | -$3.2M | $5.6M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | Not filed | -$4.0M | -$4.2M | $5.0M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | Not filed | -$5.5M | -$2.3M | $9.2M | No debt tags | Needs four quarters | 10-Q 2026-05-11 |
| Q4 2025 2025-12-31 | Not filed | -$1.5M | -$1.1M | $1.9M | No debt tags | Needs four quarters | 10-K 2026-03-13 |
| Q3 2025 2025-09-30 | Not filed | -$1.2M | -$1.3M | $3.0M | No debt tags | Needs four quarters | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | Not filed | -$3.1M | -$2.5M | $4.3M | No debt tags | Needs four quarters | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | Not filed | -$8.2M | -$2.1M | $1.9M | $2.3M | Needs four quarters | 10-Q 2026-05-11 |
| Q4 2024 2024-12-31 | $1K | -$5.8M | -$3.5M | $1.7M | No debt tags | $582K | 10-K 2026-03-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-03-16 |
| Latest annual report | 10-K | 2026-03-13 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K | 2026-10-15 |
| Latest proxy | DEFA14A | 2026-05-11 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.6% |
| 1 month | -24.0% |
| 3 months | -60.9% |
| Year to date | -94.4% |
| 1 year | -95.7% |
| From 52-week high | -95.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| ERNAW | Ernexa Therapeutics Inc. Warrants | $0.0257 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DRMA | Dermata Therapeutics Inc. | $0.5985 | -3.65% | $3.0M |
| NRSN | NeuroSense Therapeutics Ltd. | $1.56 | -7.40% | $3.0M |
| MBIO | Mustang Bio Inc. | $0.3947 | -6.34% | $3.0M |
| PPBT | Purple Biotech Ltd. | $1.68 | +3.70% | $2.7M |
| GRI | GRI Bio Inc. | $1.40 | -18.60% | $3.1M |
| EOCN | Eocene Ltd. | $2.53 | +5.86% | $2.6M |
| REVB | Revelation Biosciences Inc. | $3.82 | -10.43% | $2.6M |
| APUS | Apimeds Pharmaceuticals US Inc. | $2.04 | -8.52% | $3.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier